--

National Institutes of Health: 

  • Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2018, 2019, and 2020 (P50)This FOA invites applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPOREs). The program will fund P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer or a related group of cancers. In addition, a SPORE may focus on cross-cutting themes such as pediatric cancers or cancer health disparities (see the P20 opportunity below as well). The research supported through this program must be translational and must stem from research on human biology using cellular, molecular, structural, biochemical, and/or genetic experimental approaches. SPORE projects must have the goal of reaching a translational human endpoint within the project period of the grant. LOI deadline: December 15, 2017. Full proposals due: January 25, 2018 (January 17 in OSP/BMRA). Budget: Up to $1.4 million direct costs per year for up to 5 years. 
  • Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities (P20)This FOA invites applications for development of translational research programs that are focused upon investigating cancer health disparities. The P20 grants will support feasibility and planning activities to build cancer health disparities research programs. It is the expectation that the research programs developed by the P20 awards should be competitive with other applications for a full Specialized Programs of Research Excellence (SPORE--see above), addressing cancer health disparities as a cross-cutting research theme. LOI deadline: December 18, 2017. Full proposals due: January 18, 2018 (January 8 in OSP/BMRA). Budget: Up to $800,000 direct costs per year for up to 3 years. 
  • Immuno-Oncology Translation Network (IOTN)Four companion FOAs will support the establishment of the IOTN with the following components:
    • Cancer Immunotherapy Consortium (CIC): The CIC will be composed of organ site-specific Cancer Immunotherapy Research Projects (U01) (to be supported by RFA-CA-17-045) and Cancer Immunoprevention Research Projects (to be supported by RFA-CA-17-046). The CIC will form an integrated network of multi-disciplinary, collaborative teams with the overarching goals of accelerating the development of improved immunotherapeutic strategies capable of eliminating established cancers or preventing cancers before they occur. Approximately 10-12 U01s are expected to be awarded in FY18.
    • Data Management and Resource-Sharing Center (DMRC): The DMRC (one U24, to be supported by RFA-CA-17-047) will provide overall support, and facilitate collaboration among the adult IOTN-funded components. The DMRC will also promote scientific outreach with other Cancer Moonshot initiatives and the larger scientific community.
    • Cellular Immunotherapy Data Resource (CIDR): The CIDR (one U24, to be supported by RFA-CA-17-048) will support a data registry for collecting outcomes of patients receiving cellular immunotherapies, that could be utilized for observational studies or inform subsequent pre-clinical studies and clinical trials.
LOIs deadline: December 16, 2017. Full proposals due: January 16, 2018 (January 7 in OSP/BMRA). 
  • Biomedical Technology Research Resource (P41): Encourages grant applications for national Biomedical Technology Research Resources (BTRR). These Resources conduct research and development of new or improved technologies driven by the needs of basic, translational, and clinical researchers. The Resources are charged to make their technologies available to the research community in a sustainable manner, to provide user training, and to disseminate the Resource’s technologies and experimental results. Resources should be at the leading edge of their field with respect to both technology development and engagement of the relevant research community. Up to $800,000 will be awarded for up to five years. Deadline: January 25, 2018; and May 25, 2018.

The Elsa U. Pardee Foundation:

  • Grant applications to fund research to investigators in United States non-profit institutions proposing research directed toward identifying new treatments or cures for cancer. By design, there are no limits set on the grant amount that can be requested. It must be reasonably and clearly supported by the scope of the project outlined in the application. Applications requesting more than 15% overhead are usually not considered. Deadline: December 31, 2017. 

COBRE for Skeletal Health and Repair:

  • Pilot Project Grant Program: The purpose of this grant program is to stimulate research activities necessary to advance multidisciplinary research projects in musculoskeletal tissues for the purpose of attracting external funding from both federal and foundation sources. The proposal must have a realistic potential for future success in attracting external support. Funds should be applied to pilot research necessary to advance such proposals. These funds are not intended to supplement ongoing NIH funded projects (R01 or P01). They are to support new research conducted by investigators who have not yet been the PI of R01-type funds, or by established investigators who are making a significant change to their career. The applicants should identify the external sponsor they intend to approach with this pilot data and should provide a description of the project for which external support will be sought, a budget estimate, and a timeline for submission. In consultation with the external advisory committee of COBRE, awards of up to $50,000/year will be made by the COBRE. Deadline: March 1, 2018.

Department of Health and Human Services: 

  • Maximizing Investigators' Research Award for Early Stage Investigators (R35): The grant will provide support for the program of research in an early stage investigator's laboratory that falls within the mission of NIGMS. For the purpose of this FOA, a program of research is the collection of projects in the investigator's lab that are relevant to the mission of NIGMS. Budget: Applications may request up to $250,000 in direct costs per year for a maximum project period of five years. Applications due October 3, 2018; and October 3, 2019 by 5 p.m. local time of applicant organization. 

National Institute of Allergy and Infectious Diseases (NIAID): 

  • Physician-Scientist Pathway to Independence Award (K99/R00): This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIAID research support during this transition to help awardees launch competitive, independent research careers in biomedical fields and thereby help to address the national physician-scientist workforce shortage. Deadlines: NIH’s Standard Due Dates and Standard AIDS Dates apply.

Diabetes Research & Wellness Foundation: 

  • Research applications related to finding the cause, prevention, treatment, and cure of diabetes and its complications. Applications accepted year-round. 

National Institutes of Health & Department of Health and Human Services:

University of Vermont I-Trep Program:

Upcoming Opportunities: